Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yea I am kicking myself for not having any powder
Is that you on the whack?
Yes and hoping it can stabilize and get back to trading around .05! Still having faith here and itching to hear about the EU.
Just got this in from OTCPICKS Newsletter
STOCKS TO WATCH
GLOBAL HEALTH VENTURES INCORPORATED (OTCBB: GHLV)
"Up 24.32% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/GHLV.php
Global Health Ventures is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.
GHLV News:
September 16 - BetterInvesting National Convention to Host Global Health Ventures Inc., CEO to Present GHLV Sublingual Drug Delivery System Sept. 17, 2011
Global Health Ventures Inc. (OTCBB: GHLV), a specialty pharmaceutical company with a focus on sublingual drug delivery, announced that CEO Dr. Hassan Salari will introduce the company to BetterInvesting National Convention participants in a corporate presentation at 1:20 p.m. on Saturday, Sept. 17. Dr. Salari will discuss the company's Sublingual Drug Delivery System and the company's first product in clinical trials, X-Excite, along with the company's commercialization strategy and the management appointment of Dr. Lola Maksumova, M.D., Ph.D., as Senior Vice President and Chief Operating Officer.
Global Health Ventures has become a corporate sponsor of BetterInvesting, one of the largest non-profit retail investor organizations in the U.S. This sponsorship represents one facet of what will be Global Health Ventures' ongoing efforts to increase its exposure to the retail investor community.
Dr. Salari said: "We are pleased to present to the many investors at the BetterInvesting National Convention and are excited to have a platform for review by the investment community. The corporate presentation allows us to educate potential shareholders in more detail about our goals to commercialize our sublingual drug delivery system."
Why don't we have a news icon showing up for the board?
Another similar NEWS piece
News for 'ECDC' - (East Coast Diversified Corporation Rolls Out Mobile App)
Sep 21, 2011 (Close-Up Media via COMTEX) -- East Coast Diversified Corporation,
through its subsidiary EarthSearch Communications, announced it continues to
expand its new mobile division with the development of a mobile app to assist
visually impaired individuals to navigate workplace facilities and live a more
full life using RFID technology.
In a release dated Sept. 16, the Company said Kayode Aladesuyi, the CEO of
EarthSearch Communications said, "The Company is very excited about the
development of our new mobile division of EarthSearch. In addition to developing
our current host of GPS and RFID products and solutions, we feel our new mobile
division will only complement our current business, and should bring in more
rapid expansion for our mobile operations to assist in providing immediate
growth and value for our current shareholders."
"I was personally inspired about this device and its application, when I see all
the aesthetics developed for our brave men and women in uniform coming home with
arms, limbs and other impairments, you begin to wonder about those that are
vision impaired. This is the least we can do for them and all the people around
the globe with blindness and other vision impairment, we have the technology why
not use it for a good cause," said Kayode Aladesuyi, CEO ECDC.
The mobile application currently under development will assist visually impaired
individuals, through the use of RFID technology, it will integrate other
navigation intelligence that allow the blind to navigate workplace or government
facilities and other public places for such areas as restrooms, fire exits, and
facility layouts, all through the use of the mobile device and EarthSearch RFID
technology.
This mobile RFID technology will be a functional solution that will allow
business to fully comply with the Disabilities Act of 1990 by providing RFID
centric workplace that will enable the vision impaired to integrate into the
workforce.
EarthSearch Communications is an ECDC Company.
((Comments on this story may be sent to newsdesk@closeupmedia.com))
Copyright Close-Up Media, Inc. 2011. All Rights reserved
-0-
INDUSTRY KEYWORD: Wireless_News
NEWS
News for 'ECDC' - (EarthSearch Develops RFID Mobile Device for Vision Impaired)
Sep 21, 2011 (Close-Up Media via COMTEX) -- East Coast Diversified Corp.,
through its subsidiary EarthSearch Communications, Inc., has announced it
continues to expand its new mobile division with the development of a mobile app
to assist visually impaired individuals to navigate workplace facilities and
live a more full life using RFID technology.
The Company said that the new mobile application currently under development
will assist visually impaired individuals, through the use of RFID technology,
will integrate other navigation intelligence that allow the blind to navigate
workplace or government facilities and other public places for such areas as
restrooms, fire exits, and facility layouts, all through the use of the mobile
device and EarthSearch RFID technology. This new mobile RFID technology will be
a functional solution that will allow business to fully comply with the
Disabilities Act of 1990 by providing RFID centric workplace that will enable
the vision impaired to integrate into the workforce.
"I was personally inspired about this device and its application, when I see all
the aesthetics developed for our brave men and women in uniform coming home with
arms, limbs and other impairments, you begin to wonder about those that are
vision impaired. This is the least we can do for them and all the people around
the globe with blindness and other vision impairment, we have the technology why
not use it for a good cause," said Kayode Aladesuyi, CEO ECDC.
East Coast Diversified noted that this new mobile application comes on the heels
of the launch of the SchoolsConnects transportation and class attendance
monitoring system, which is a mobile app solution that provides a platform for
schools and parents to monitor the safety of students using GPS, RFID, MMS and
SMS text message technology. EarthSearch's SchoolsConnects system is currently
being delivered to two schools in the nation of Dubai under an initial program
and discussion are ongoing with several US school districts for deployment.
In addition to developing its own brand of EarthSearchMobile applications, the
Company reported that it will also embark on expanding its new mobile division
through possible acquisitions in the areas of social networking, and corporate
enterprise developers. The Company is currently reviewing several operational
and revenue generating mobile development and content providers for potential
acquisitions under the EarthSearchMobile umbrella.
Kayode Aladesuyi, the CEO of EarthSearch Communications said, "The Company is
very excited about the development of our new mobile division of EarthSearch. In
addition to developing our current host of GPS and RFID products and solutions,
we feel our new mobile division will only complement our current business, and
should bring in more rapid expansion for our mobile operations to assist in
providing immediate growth and value for our current shareholders."
EarthSearch Communications, an ECDC Company is a US-based business whose
flagship product, LogiBoxx, integrates GPS and RFID at the hardware level. When
combined with its proprietary Global Asset Tracking and Identification System
(GATIS) middleware, LogiBoxx and GATIS become the centerpieces of a LogiBoxx
Certified Solution.
More Information:
www.earthsearch.us
www.schoolsconnects.com
((Comments on this story may be sent to newsdesk@closeupmedia.com))
Copyright Close-Up Media, Inc. 2011. All Rights reserved
-0-
Nope didn't work but thanks. Go SWME
still on my free membership, saving cash for SWME :)
SWME just popped up on the breakout boards. Hopefully can create some volume today http://investorshub.advfn.com/boards/hotboardsrelative.aspx
I too am holding out on those double digits! Hoping to add where I can. Hoping to not have the opportunity much longer :)
Im here, still holding strong. No more cash to add though on those dips. Waiting for my run Go SWME
do you know something we don't? We've all been waiting on financials for awhile now.
Yup agree. Good looking on technical and solid volume. Hopefully some news soon. Go VPRO
Another bid whack. Buy the ask people!
Does anybody know anything special on that RM front?
Why not just stop in and ask?
NEWS!
News for 'GHLV' - (Better Investing National Convention to Host Global Health Ventures Inc. CEO to Present GHLV Sublingual Drug Delivery System September 17th, 2011)
VANCOUVER, British Columbia, Sep 15, 2011 (GlobeNewswire via COMTEX) -- Global
Health Ventures Inc. (OTCBB:GHLV), a specialty pharmaceutical company with focus
on sublingual drug delivery, is pleased to announce, CEO Dr. Hassan Salari will
introduce the company to the Better Investing National Convention participants
in a corporate presentation on Saturday September 17th at 1:20 pm. Dr. Salari
will discuss the company's Sublingual Drug Delivery System and the company's
first product in clinical trials, X-Excite, along with the company's
commercialization strategy and the management appointment of Dr. Lola Maksumova,
MD, Ph.D., as Senior Vice President and Chief Operating Officer.
Global Health Ventures has become a corporate sponsor of Better Investing, one
of the largest non-profit retail investor organizations in the U.S. This
sponsorship represents one facet of what will be Global Health Ventures ongoing
efforts to increase its exposure to the retail investor community.
Dr. Hassan Salari, PHD, C.E.O. expressed, "We were pleased to present to the
many investors of the Better Investing National forum and are excited to have a
platform for review by the investment community. The corporate presentation
allows us to educate potential shareholders in more detail about our goals to
commercialize our sublingual drug delivery system."
For a current corporate fact sheet
http://premierstocks.tv/images/company_links/GHLVlogo.pdf
About Sublingual Technology
The Company's drug formulation is designed to enhance the delivery of the
medical products faster to the body than current oral formulations. This design
enables the vast majority of pharmaceutical drugs to be rapidly absorbed through
the mucosal membrane (tissues of the mouth) quickly. This technology works well
for drugs that need faster results and have major side effects associated with
gastrointestinal and/or liver break down. It is scientifically accepted that the
sublingual drug delivery route is the fastest and most efficient way of drug
delivery after direct injection.
About Global Health Ventures (OTCBB:GHLV) is a specialty pharmaceutical company
with expertise in drug delivery and formulation. The Company has developed a new
formulation for drug delivery via the sublingual (under the tongue) route. This
unique method delivers drugs to the bloodstream quickly with less drug breakdown
in the liver or gastrointestinal system, a process that can reduce side effects
associated with the drugs. The Company's lead therapeutic product is a male
sexual enhancement drug that is delivered via sublingual route and is called
X-Excite. In human studies, X-Excite has been shown to reach the blood stream
faster than the oral route of delivery. The company has initiated the
development of non steroidal anti inflammatory drugs (NSAIDs). Several NSAIDs
have been demonstrated to carry gastrointestinal side effects which prevent
patients from using them effectively. The Company's has the drug "Relax-B" is
also under development in Canada for anxiety. And, the next drug will be an
anti-migraine drug. The Company plans to use the same technology to deliver a
vast number of other FDA approved drugs that require faster delivery, or reduced
hepatic and gastrointestinal side effects. These include anti-stress, sleeping
disorders, pain killers, anti-allergy medications, heart and lung medication,
migraine and addiction replacement therapies.
About BetterInvesting
Empowering investors since 1951, BetterInvesting is
the brand identity of the National Association of Investors Corporation, a
national, nonprofit association with members consisting of individual investors
and investment clubs. With headquarters in Madison Heights, Mich.,
BetterInvesting is considered the voice of the individual investor, as well as
the pioneer of the modern investment club movement. BetterInvesting is dedicated
to providing a sound program of investment education and information to help its
members become successful long-term, lifetime investors. For more information
about BetterInvesting, visit its website at www.betterinvesting.org or call toll
free (877) 275-6242. For additional BetterInvesting data and news releases,
visit the Media Center at www.betterinvesting.org/mediacenter.
Notice Regarding Forward Looking Statements -This press release includes
forward-looking statements that involve a number of risks and uncertainties,
including the success of the products in commercializing and developing.
Further, the risks involve the ability of the Company to raise capital to fund
its operations and the capital requirements for the development and marketing of
its products. Investors are encouraged to review the risk factors listed or
described from time to time in the Company's filings (10K) with the Securities
and Exchange Commission.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Global Health Ventures Inc.
By Staff
CONTACT: CONTACT: Premier Media Service Inc.
Kelly Black, President
480 649-8224
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
I emailed the CEO months back and he said they were working on things but it was going to take around a year. After the last scam that was run here by that group I don't think people will be touching this stock.
Where's the investors update?
I had an order in the other day when the price was around .003 and it took two trading days to fill! Low float, strong hands.
Damn MMs playing this one until they damn well please. Anyone know what caused the run back in the may to occur? Was it all technical? Go SWME!
Need to tickle that ask. Where is Gregg when we need him!
horrible day today. hopefully a bounce back tomorrow.
Haha yea I'd like to see that run but would also like to see it sustain them future gains!
Yea and look at it now...
This is getting ridiculous. Time to fly SWME. And I thought those .003s were cheap.
Haha just giving you a hard time. Wishing I could add down here. Waiting for take off. Go SWME!
Hey I thought we weren't mentioning news! Let's not be hypocritical :)
Oh I wasn't going to buy it. Just thought that the publication date of a few days ago was interesting. Hope to see this bounce back asap. Kicking myself for not having funds cleared.
Looks like this company recently did a report on SWME. Are these things ever worth the money? Perhaps an indication that things might be coming into place?
http://www.alacrastore.com/storecontent/Morningstar_Equity_Research-Swiss_Medica_Inc-2064-8199
.0022x.0025 are you kidding me!
Yes very annoying. SOME people like to sit on the bid around here and the MMs like to fill it. I think it's going to be like this for awhile until we see buying pressure.
If I am not mistaken, the majority owner of VPRO is a company from India. I think I saw that in the last filing.
Here we go...
VIROPRO, INC. (“Viropro” or the “Company”) conducts operations through its subsidiaries, Viropro International Inc. (“VPRI”) and Biologics Process Development Inc. of San Diego CA (”BPD”), and specializes in the transfer of its technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis or multiple sclerosis. The Company’s principal objective is to provide Contractual Research and Manufacturing Services to biotech and biopharmaceutical companies in global markets. Biotech and Biopharma are cutting edge industries calling for highly specialized installations, equipments, and highly skilled and highly educated personnel. Viropro owns and has access to such specialized resources.
Viropro draws most of its revenues from services biotech and biopharma industries on a cost plus percentage basis. This percentage varies according to the type of services rendered.
Viropro enjoys close working relations with some of the leading biotech research institutes in North America, one of which is the Biotech Research Institute (BRI) in Montreal, Canada, a constituent of the National Research Council of Canada. Viropro has licensed from BRI a high-efficiency expression system platform for antibody production.
In April 14, 2010, Intas Biopharmaceuticals Ltd. (“Intas”) of India, became the controlling shareholder of Viropro. Intas is one of India’s leading biotechnology companies, with a “Products” business and a “Contract Services” business. It is the only biotech company in India that has a cGMP (current Good Manufacturing Practice) biologics facility approved by the European Medicines Agency and has brought four biopharmaceuticals to the market in as many years.
Viropro’s strategic plan is to develop into a premier Biotechnology Contract Research and Manufacturing Services (“CRAM”) company, within a five-year timeframe. The intention is to have our operating subsidiaries provide key services using modern biotechnology principles in the area of biologics process development and cGMP-based biologics contract manufacturing.
Our resident whackers are back. Seems as if people have their bids in at the 200MDA and just wait for the MMs to fill. Time to run SWME!
Yea why not? Dr S has always stated that a buyout is a viable option. You can't tell me that their EU trials did not make it onto the radars of the big pharma boys. GHLV is competition and the most successful people are always aware of the competition. He seems to be quite confident that his formulation for sublingual use is above the rest.
Yea the interest is great. Do you by any chance know when the initial offer was made to them? They have an interesting chart. I am still hoping GHLV receives a buyout. For all we know, offers have been made.
Yea that would be nice. Although that company closed today at $6.00. Good find.
#2 on the breakout boards. http://investorshub.advfn.com/boards/hotboardsrelative.aspx
I was in a penny last week that ran 400% in one day.
One would think that Dr. S knew that a company like Pfizer, would be able to extend the life of the patent of their most notable product. I want a buy out or licensing deals. Give it to me GHLV!